Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

PVI/Seronet Study Group

doi:10.1016/j.ccell.2021.09.015

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

PVI/Seronet Study Group

Research output: Contribution to journal › Letter › peer-review

64 Scopus citations

Original language	English
Pages (from-to)	1442-1444
Number of pages	3
Journal	Cancer Cell
Volume	39
Issue number	11
DOIs	https://doi.org/10.1016/j.ccell.2021.09.015
State	Published - 8 Nov 2021

Access to Document

10.1016/j.ccell.2021.09.015

Cite this

@article{9e24c21a1aac48a29194f18dcb73e770,

title = "Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma",

author = "{PVI/Seronet Study Group} and Adolfo Aleman and Bhaskar Upadhyaya and Kevin Tuballes and Katerina Kappes and Gleason, {Charles R.} and Katherine Beach and Sarita Agte and Komal Srivastava and D. Andre and A. Azad and R. Banu and Berm{\'u}dez-Gonz{\'a}lez, {M. C.} and G. Cai and C. Cognigni and K. David and D. Floda and A. Firpo and G. Kleiner and N. Lyttle and W. Mendez and Mulder, {L. C.F.} and R. Mendu and A. Oostenink and A. Rooker and K. Russo and A. Salimbangon and M. Saksena and A. Shin and L. Sominsky and {Van Oekelen}, Oliver and Vanessa Barcessat and Nina Bhardwaj and Seunghee Kim-Schulze and Sacha Gnjatic and Brian Brown and Carlos Cordon-Cardo and Florian Krammer and Miriam Merad and Sundar Jagannath and Ania Wajnberg and Viviana Simon and Samir Parekh",

note = "Funding Information: We thank study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. None of this work would be possible without their contributions. We acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai. We acknowledge the lab of Alessandro Sette at the La Jolla Institute for Immunology for generously providing SARS-CoV-2 peptides. Samir Parekh is supported by National Cancer Institute (NCI) grants R01 CA244899 and CA252222 and receives research funding from Amgen , Celgene /BMS, and Karyopharm . This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 , NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) contracts HHSN272201400008C and HHSN272201400006C , and NIAID grants U01AI141990 and U01AI150747 ; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384) ); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute , National Institutes of Health, under contract 75N91019D00024 , Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. Funding Information: We thank study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. None of this work would be possible without their contributions. We acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai. We acknowledge the lab of Alessandro Sette at the La Jolla Institute for Immunology for generously providing SARS-CoV-2 peptides. Samir Parekh is supported by National Cancer Institute (NCI) grants R01 CA244899 and CA252222 and receives research funding from Amgen, Celgene/BMS, and Karyopharm. This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) contracts HHSN272201400008C and HHSN272201400006C, and NIAID grants U01AI141990 and U01AI150747; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384)); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. V.S. A.W. S.P. and PVI/Seronet Study Group provided conceptualization, methodology, analysis, and resources for this work. A.A. K.K. K.B. K.S. S.A. C.R.G. and PVI/Seronet Study Group were involved in organizational aspects of the clinical studies, patient recruitment, data collection, and analysis. A.A. O.V.O. S.A. C.R.G. C.C.C. and F.K. were involved in design, data collection, analysis, visualization, and interpretation of serological data. A.A. B.U. K.T. V.B. S.G. and S.K.S. were involved in design, execution, analysis, visualization, and interpretation of T and B cell assays. S.J. A.W. S.P. and V.S. were involved in different aspects of patient care. B.U. N.B. S.G. B.B. M.M. S.J. A.W. V.S. and S.P. provided interpretation of the data and conceptualization of the first manuscript draft. A.A. B.U. A.W. V.S. and S.P. contributed to the writing of the first manuscript draft. All coauthors provided critical edits to the initial manuscript draft and approved the final version. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardo-Cordon are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees from Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine. Sacha Gnjatic reports past consultancy and/or advisory roles for Merck and OncoMed and past or current research funding from Bristol-Myers Squibb, Genentech, Boehringer-Ingelheim, Pfizer, Takeda, and Regeneron. Nina Bhardwaj reports consultancy and/or advisory roles for Novartis, Apricity, Rome Therapeutics, CureVac, Genotwin, BioNTech, Gildea, Tempest Therapeutics, Boehringer Ingelheim, and Rubis Therapeutics. Other authors report no relevant conflicts of interest.",

year = "2021",

month = nov,

day = "8",

doi = "10.1016/j.ccell.2021.09.015",

language = "English",

volume = "39",

pages = "1442--1444",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

AU - PVI/Seronet Study Group

AU - Aleman, Adolfo

AU - Upadhyaya, Bhaskar

AU - Tuballes, Kevin

AU - Kappes, Katerina

AU - Gleason, Charles R.

AU - Beach, Katherine

AU - Agte, Sarita

AU - Srivastava, Komal

AU - Andre, D.

AU - Azad, A.

AU - Banu, R.

AU - Bermúdez-González, M. C.

AU - Cai, G.

AU - Cognigni, C.

AU - David, K.

AU - Floda, D.

AU - Firpo, A.

AU - Kleiner, G.

AU - Lyttle, N.

AU - Mendez, W.

AU - Mulder, L. C.F.

AU - Mendu, R.

AU - Oostenink, A.

AU - Rooker, A.

AU - Russo, K.

AU - Salimbangon, A.

AU - Saksena, M.

AU - Shin, A.

AU - Sominsky, L.

AU - Van Oekelen, Oliver

AU - Barcessat, Vanessa

AU - Bhardwaj, Nina

AU - Kim-Schulze, Seunghee

AU - Gnjatic, Sacha

AU - Brown, Brian

AU - Cordon-Cardo, Carlos

AU - Krammer, Florian

AU - Merad, Miriam

AU - Jagannath, Sundar

AU - Wajnberg, Ania

AU - Simon, Viviana

AU - Parekh, Samir

N1 - Funding Information: We thank study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. None of this work would be possible without their contributions. We acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai. We acknowledge the lab of Alessandro Sette at the La Jolla Institute for Immunology for generously providing SARS-CoV-2 peptides. Samir Parekh is supported by National Cancer Institute (NCI) grants R01 CA244899 and CA252222 and receives research funding from Amgen , Celgene /BMS, and Karyopharm . This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 , NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) contracts HHSN272201400008C and HHSN272201400006C , and NIAID grants U01AI141990 and U01AI150747 ; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384) ); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute , National Institutes of Health, under contract 75N91019D00024 , Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. Funding Information: We thank study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. None of this work would be possible without their contributions. We acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai. We acknowledge the lab of Alessandro Sette at the La Jolla Institute for Immunology for generously providing SARS-CoV-2 peptides. Samir Parekh is supported by National Cancer Institute (NCI) grants R01 CA244899 and CA252222 and receives research funding from Amgen, Celgene/BMS, and Karyopharm. This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) contracts HHSN272201400008C and HHSN272201400006C, and NIAID grants U01AI141990 and U01AI150747; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384)); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. V.S. A.W. S.P. and PVI/Seronet Study Group provided conceptualization, methodology, analysis, and resources for this work. A.A. K.K. K.B. K.S. S.A. C.R.G. and PVI/Seronet Study Group were involved in organizational aspects of the clinical studies, patient recruitment, data collection, and analysis. A.A. O.V.O. S.A. C.R.G. C.C.C. and F.K. were involved in design, data collection, analysis, visualization, and interpretation of serological data. A.A. B.U. K.T. V.B. S.G. and S.K.S. were involved in design, execution, analysis, visualization, and interpretation of T and B cell assays. S.J. A.W. S.P. and V.S. were involved in different aspects of patient care. B.U. N.B. S.G. B.B. M.M. S.J. A.W. V.S. and S.P. provided interpretation of the data and conceptualization of the first manuscript draft. A.A. B.U. A.W. V.S. and S.P. contributed to the writing of the first manuscript draft. All coauthors provided critical edits to the initial manuscript draft and approved the final version. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardo-Cordon are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees from Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine. Sacha Gnjatic reports past consultancy and/or advisory roles for Merck and OncoMed and past or current research funding from Bristol-Myers Squibb, Genentech, Boehringer-Ingelheim, Pfizer, Takeda, and Regeneron. Nina Bhardwaj reports consultancy and/or advisory roles for Novartis, Apricity, Rome Therapeutics, CureVac, Genotwin, BioNTech, Gildea, Tempest Therapeutics, Boehringer Ingelheim, and Rubis Therapeutics. Other authors report no relevant conflicts of interest.

PY - 2021/11/8

Y1 - 2021/11/8

UR - http://www.scopus.com/inward/record.url?scp=85118481077&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.09.015

DO - 10.1016/j.ccell.2021.09.015

M3 - Letter

C2 - 34706273

AN - SCOPUS:85118481077

SN - 1535-6108

VL - 39

SP - 1442

EP - 1444

JO - Cancer Cell

JF - Cancer Cell

IS - 11

ER -